Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.
FDA approves GSK's pandemic H1N1 vaccine
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that the US Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for its unadjuvanted influenza A (H1N1) pandemic vaccine.
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals, Inc., announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.
WHO Grants Prequalification for Global Use to GSK's 10-Valent Synflorix⢠Vaccine
- Details
- Category: GlaxoSmithKline
The World Health Organization (WHO) has awarded prequalification for global use of Synflorix™, GlaxoSmithKline Biologicals' pneumococcal conjugate vaccine. This is the first prequalification for a vaccine against pneumococcal disease, which is a life-threatening disease affecting many children under five in developing countries.
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.
Novartis to expand its human vaccines presence in China
- Details
- Category: Novartis
Novartis has reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry leader in this country and expand the Group's limited presence in this fast-growing market segment.
New Merck Begins Operations
- Details
- Category: Merck
Merck & Co., Inc. (NYSE: MRK) outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value.
More Pharma News ...
- World's largest malaria vaccine trial now underway in seven African countries
- Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China
- Pfizer and Medivation Initiate Two Phase 3 Trials of Dimebon
- Abbott Completes Acquisition of Evalve, Inc.
- Sanofi-aventis delivers a solid performance in third quarter 2009
- Lilly CEO Lechleiter Calls for Repair of the 'Engine of Biopharma Innovation'
- Novartis on track to deliver Influenza A (H1N1) vaccine for the US